Navigation Links
Acute Pain Global Clinical Trials Review, H2, 2013
Date:11/27/2013

ical Trial Overview of Leiden University Medical Center 59
Albert Einstein College of Medicine of Yeshiva University 60
Clinical Trial Overview of Albert Einstein College of Medicine of Yeshiva University 60
The Cleveland Clinic 61
Clinical Trial Overview of The Cleveland Clinic 61
Mayo Clinic 62
Clinical Trial Overview of Mayo Clinic 62
Oslo University Hospital 63
Clinical Trial Overview of Oslo University Hospital 63
University Medicine Greifswald 64
Clinical Trial Overview of University Medicine Greifswald 64
Royal Perth Hospital 65
Clinical Trial Overview of Royal Perth Hospital 65
Yonsei University 66
Clinical Trial Overview of Yonsei University 66
University of Zurich 67
Clinical Trial Overview of University of Zurich 67
National Institutes of Health Clinical Center 68
Clinical Trial Overview of National Institutes of Health Clinical Center 68
North West London Hospitals NHS Trust 69
Clinical Trial Overview of North West London Hospitals NHS Trust 69
Los Angeles Biomedical Research Institute 70
Clinical Trial Overview of Los Angeles Biomedical Research Institute 70
National Health and Medical Research Council 71
Clinical Trial Overview of National Health and Medical Research Council 71
Five Key Clinical Profiles 72
Appendix 120
Abbreviations 120
Definitions 120
Research Methodology 121
Secondary Research 121
About GlobalData 122
Contact Us 122
Disclaimer 122
Source 123

List of Tables

Acute Pain Therapeutics Market, Global, Clinical Trials by Zone, 2013* 8
Acute Pain Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 9
Acute Pain Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 10
Acute Pain Therapeutics Clinical Trials, Asia-Pacific, Top Fiv
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
2. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
3. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
4. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
5. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
6. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
7. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
8. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
10. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
11. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... "Company"), a diversified life sciences company, today announced that ... authorized shares of common stock of the Company from ... held on July 27, 2015 at the Law Offices ... Meeting").   At the Special Meeting, there were 480,655,929 shares ...
(Date:7/28/2015)... MORRISTOWN, N.J. , July 28, 2015 /PRNewswire/ ... its second Phase 1 clinical trial with MMI-0100, ... that is being developed for pulmonary disorders characterized ... the United Kingdom , is ... study further evaluating the safety and tolerability of ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 /PRNewswire/ ... announced its financial results for the second quarter ... grew nearly 300% as compared to the second ... launched," said Roger Jeffs, Ph.D., United Therapeutics, President ... sales was due to an increase in the ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... Products offer biologically safer water through point-of-use ... ... NEP ),a medical device company, announced today that it will ... Healthcare,Engineering (ASHE) Conference and Technical Exhibition in National Harbor,Maryland, July 20th-23rd, ...
... RICHMOND, Va., July 14, 2008 Insmed Inc.,(Nasdaq ... for unmet medical needs, today announced that the,Company ... (RBC) to act as,its strategic financial advisor., ... are dedicated,to enhancing shareholder value and will be ...
... PARK, Calif., July 14 Pacific Biosciences,announced today ... Series E private,equity financing round. The proceeds will ... company,s innovative single-molecule, real-time,(SMRT(TM)) DNA sequencing platform., ... and Intel,Capital, Intel Corporation,s global investment organization. Other ...
Cached Biology Technology:Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 2Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 3Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 4Insmed Retains RBC Capital Markets as Strategic Financial Advisor 2Insmed Retains RBC Capital Markets as Strategic Financial Advisor 3Pacific Biosciences Raises $100 Million to Fund Commercial Product Development 2
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... puzzle are emerging in the latest study from a research ... Medicine and The Children,s Hospital of Philadelphia (CHOP). The study ... missing or extra copies of DNA segments were ... but not in the healthy controls. The findings are published ...
... increase in area burned by wildfires in the Western United ... fire seasons alone, but a complex relationship between climate and ... conducted by U.S. Forest Service and university scientists. The study ... States to date and appears in the current issue of ...
... can only marvel at the way that dolphins, whales ... perfectly adapted for maximum aquatic agility. However, no one ... water; the hydrodynamic lift that they generate, the drag ... and Paul Weber from Duke University teamed up with ...
Cached Biology News:Further gene mutations linked to autism risk 2In the warming West, climate most significant factor in fanning wildfires' flames 2Dolphins get a lift from delta wing technology 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Asb-2 (Ankyrin repeat and SOCS box-containing protein) ... peptides containing amino acids 75-93 and 348-368 ... (Imgenex Catalog No. 40149) can be used ... react with mouse and rat Asb-2, based ...
... Monoclonal Antibody, Unconjugated Applications: ... ICC: Use at an assay dependent dilution. WB: ... ug/ml, this concentration is determined using a whole ... kDa. Not tested in other applications. Optimal ...
Biology Products: